Nektar Therapeutics (NAS:NKTR)
$ 1.07 -0.11 (-9.32%) Market Cap: 197.37 Mil Enterprise Value: 80.51 Mil PE Ratio: 0 PB Ratio: 3.96 GF Score: 59/100

Nektar Therapeutics preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study Transcript

Sep 26, 2019 / 12:30PM GMT
Release Date Price: $17.56 (-6.60%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Nektar Therapeutics Conference Call. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.

Jennifer Ruddock
Nektar Therapeutics - SVP of Strategy & Corporate Affairs

Thank you, Crystal. Welcome, everyone, and thank you for joining us on today's call. Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's proprietary drug candidate, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks which are detailed in our filings with the SEC, including the Form 10-Q filed on August 9, 2019. We undertake no obligation to update these forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot